深入认识慢性阻塞性肺疾病的急性加重_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

马千里 ,  王长征

第三军医大学新桥医院呼吸内科(重庆 400037);

Corresponding author：

王长征, Email: czwang@netease.com

Keywords：

DOI：

10.7507/1671-6205.2016051

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 马千里, 王长征. 深入认识慢性阻塞性肺疾病的急性加重. Chinese Journal of Respiratory and Critical Care Medicine, 2016, 15(3): 213-215. doi: 10.7507/1671-6205.2016051 Copy

1.	Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med, 2008, 178:332-338.
2.	Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363:1128-1138.
3.	Calverley PMA, Anderson JA, Bartolome Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356:775-789.
4.	Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008, 359:1543-1554.
5.	Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371: 2013-2018.
6.	Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J, 2014, 44:1156-1165.
7.	Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23:932-946.
8.	Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 2000, 343:1902-1909.
9.	Yang L, Ma QL, Yao W, et al. Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in COPD. Respir Res, 2011, 12:142.
10.	Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014, 371:1285-1294.
11.	Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet, 2009, 374: 695-703.
12.	Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON). Lancet Respir Med, 2014, 2:187-194.

1. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med, 2008, 178:332-338.
2. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363:1128-1138.
3. Calverley PMA, Anderson JA, Bartolome Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356:775-789.
4. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008, 359:1543-1554.
5. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371: 2013-2018.
6. Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J, 2014, 44:1156-1165.
7. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23:932-946.
8. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 2000, 343:1902-1909.
9. Yang L, Ma QL, Yao W, et al. Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in COPD. Respir Res, 2011, 12:142.
10. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014, 371:1285-1294.
11. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet, 2009, 374: 695-703.
12. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON). Lancet Respir Med, 2014, 2:187-194.

Next Article
Analysis on the Clinical Characteristics and Survival of 53 Patients with Pulmonary Fibrosis Complicated with Lung Cancer

Chinese Journal of Respiratory and Critical Care Medicine

深入认识慢性阻塞性肺疾病的急性加重

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content